查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1928590

勃起功能障礙市場依產品類型、治療類型、給藥途徑、年齡層、通路、最終用戶分類，全球預測（2026-2032年）

Erectile Dysfunction Market by Product Type, Treatment Type, Route Of Administration, Patient Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，治療勃起功能障礙的藥物市場價值將達到 131.1 億美元，到 2026 年將成長到 138.2 億美元，到 2032 年將達到 181 億美元，年複合成長率為 4.70%。

關鍵市場統計數據
基準年 2025 131.1億美元
預計年份：2026年 138.2億美元
預測年份 2032 181億美元
複合年成長率 (%) 4.70%

針對勃起功能障礙的綜合框架，重點關注臨床創新、通路轉型和以患者為中心的轉變，這需要策略調整。

勃起功能障礙（ED）是一種具有重要臨床意義的疾病，其治療方法不斷發展，患者期望不斷變化，競爭也日益激烈。藥理學、醫療設備工程和遠端醫療等技術的進步正在拓展臨床醫生診斷和治療ED的方式，而知情的患者則要求治療方案便捷、耐受性好，並能改善長期生活品質。在此背景下，相關人員必須應對複雜的監管環境、通路以及快速的技術整合，才能保持競爭力。

臨床、數位化和支付方趨勢的融合將如何重塑急診生態系統中的治療路徑和商業策略

勃起功能障礙治療領域正經歷變革性的轉變，這主要得益於技術、監管和消費者趨勢的融合。首先，治療創新已不再局限於配方上的漸進式改進，而是擴展到新型給藥系統和器械治療方案的整合，這迫使人們重新評估傳統的臨床路徑。隨著臨床醫師在考慮療效的同時，也開始關注藥物的持久性、併發症情況以及與患者生活方式的契合度，這些進步最終將重塑臨床指引和轉診模式。

供應鏈風險評估和策略採購應對措施，以因應關稅對醫療設備組件、藥品原料和分銷經濟造成的成本壓力。

近期貿易政策的發展以及可能對醫療進口徵收關稅，使得治療勃起功能障礙藥物的生產商和供應商更加關注供應鏈風險。關稅會增加醫療設備和某些活性藥物原料藥的到岸成本，迫使企業重新評估供應商合約、庫存管理政策和定價策略。為此，許多企業正在加速採購多元化，評估近岸外包方案，並協商長期供應協議，以降低進口成本波動帶來的風險。

一個將治療方法、產品形式、通路、臨床環境、給藥途徑和年齡層與戰術性商業性決策聯繫起來的多維細分框架

詳細的市場細分框架對於了解勃起功能障礙治療的患者需求、商業化路徑和臨床應用至關重要。根據治療類型，市場可分為口服藥物、陰莖植入、陰莖注射劑和真空勃起裝置。在口服藥物方面，我們將重點放在PDE5抑制劑，並按分子進行詳細分析，包括阿伐那非、Sildenafil、他達拉非和伐地那非，從而能夠針對每種治療方案製定差異化的臨床和行銷策略。依產品類型分類，市場可分為醫療設備和藥品，其中醫療設備可分為陰莖植入、陰莖注射劑和真空勃起裝置。藥品則從PDE5抑制劑及其活性成分的角度進行分析，以闡明研發重點和生命週期管理方法。

監管、報銷和生產環境的區域差異是最佳化打入市場策略和跨境利用證據的關鍵因素。

區域趨勢在塑造勃起功能障礙藥物的監管路徑、報銷環境和患者獲取途徑方面發揮關鍵作用。在美洲，成熟的市場、健全的私人保險體系和完善的專業分銷基礎設施支持新型口服藥物和器械技術的快速上市，但也造成了複雜的報銷談判動態。相較之下，歐洲、中東和非洲地區（EMEA）呈現出各國監管環境和支付方環境的複雜性，需要製定量身定做的定價和市場進入策略，尤其對於高成本器材和新型治療類別而言更是如此。

綜合競爭格局分析：揭示現有製藥公司、醫療設備創新者和數位新興企業如何重塑贏得臨床醫生信任和病人青睞的路徑

勃起功能障礙領域的競爭動態呈現出多元化的態勢，既有成熟的醫療設備創新企業，也有專注於直接面對消費者的數位參與企業。領先的製藥公司在口服製劑領域保持強大的品牌知名度，並持續投資於生命週期管理、新製劑研發和聯合治療研究，以維持其臨床療效。醫療設備公司則透過改進生物相容性材料、小型化技術、提供手術技術支援以及以患者長期療效為導向的售後服務模式，不斷強化自身差異化優勢。

為領導者提供切實可行的策略性舉措，透過整合證據和管道多元化，確保臨床可信度、營運韌性和商業性規模。

尋求加速成長並維持市場地位的產業領導者應實施一系列切實有效的措施。首先，應優先進行整合證據產生工作，將隨機臨床數據與可靠的真實世界結果相結合，以支持與支付方的對話並促進臨床醫生採納。儘早投資於衛生經濟學和生活品質 (QOL) 指標將有助於減少報銷摩擦並增強產品差異化。其次，為抵禦貿易摩擦對生產的影響，企業應實現供應商和生產能力的多元化，並制定緊急時應對計畫，以確保醫療服務的連續性和關鍵零件的供應。

我們採用穩健的多方法研究途徑，整合臨床醫生訪談、監管審查和商業情報，以確保提供基於證據的策略指導。

本分析的調查方法結合了定性和定量方法，旨在提供嚴謹且可操作的見解。主要研究包括與臨床醫生、支付方、採購專業人員和患者權益倡導代表進行結構化訪談和深入討論，以收集關於治療選擇決定因素、報銷障礙和醫療服務限制的真實觀點。除了與這些相關人員的對話外，還召開諮詢小組會議，以檢驗假設並發現新興的臨床實踐模式。

策略重點的簡要概述強調了證據整合、供應鏈韌性和數位化患者路徑，以確保長期領先地位。

總而言之，隨著藥理學、醫療設備技術和數位化醫療模式的創新不斷湧現，以及支付方日益嚴格的審查和不斷變化的貿易環境，勃起功能障礙治療領域正處於戰略轉折點。成功的相關人員將是那些能夠將臨床差異化轉化為對醫療服務提供者和支付方清晰價值提案，同時建立價值鏈韌性和通路適應性的企業。不同年齡層、給藥途徑和分銷管道的患者需求之間的相互作用，凸顯了製定個人化商業化策略的必要性，這些策略應關注患者的依從性、用藥便利性和長期治療效果。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的勃起功能障礙市場

  • 裝置
    • 陰莖植入
    • 陰莖注射
    • 真空勃起裝置
  • 藥物
    • 阿伐那菲爾
    • Sildenafil
    • 他達拉非

第9章 依治療方法的勃起功能障礙市場

  • 口服藥物
  • 陰莖植入
  • 陰莖注射
  • 真空勃起裝置

第10章 依給藥途徑分類的勃起功能障礙市場

  • 注射
  • 口服
  • 外用藥物

第11章 依患者年齡層分類的勃起功能障礙市場

  • 40-49歲
  • 50-59歲
  • 60-69歲
  • 70歲或以上

第12章 按分銷管道分類的勃起功能障礙市場

  • 診所藥房
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 依最終用戶分類的勃起功能障礙市場

  • 診所
  • 居家醫療
  • 醫院

第14章 各地區勃起功能障礙市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 按群體分類的勃起功能障礙市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國勃起功能障礙市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國勃起功能障礙市場

第18章 中國勃起功能障礙市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer AG
  • Boston Scientific Corporation
  • Cipla Limited
  • Coloplast Group
  • Dong A Socio Holdings Co. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International Plc
  • Futura Medical Plc
  • GlaxoSmithKline plc
  • Lupin Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Vivus, Inc.
Product Code: MRR-92740D85F052

The Erectile Dysfunction Market was valued at USD 13.11 billion in 2025 and is projected to grow to USD 13.82 billion in 2026, with a CAGR of 4.70%, reaching USD 18.10 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.11 billion
Estimated Year [2026] USD 13.82 billion
Forecast Year [2032] USD 18.10 billion
CAGR (%) 4.70%

Comprehensive framing of the erectile dysfunction landscape highlighting clinical innovation, channel disruption, and patient-centered shifts that demand strategic recalibration

Erectile dysfunction (ED) remains a clinically significant condition with evolving therapeutic options, shifting patient expectations, and intensifying commercial competition. Advances in pharmacology, device engineering, and telehealth-enabled care pathways have expanded how clinicians diagnose and manage ED, while an increasingly informed patient population seeks treatments that align with convenience, tolerability, and long-term quality of life. Against this backdrop, industry stakeholders must navigate regulatory complexity, channel fragmentation, and rapid technological convergence to remain relevant.

Recent years have seen an acceleration of innovation across oral agents, implantable devices, and minimally invasive therapies, which has reshaped clinical decision algorithms and payer conversations. Simultaneously, the rise of digital health platforms and online pharmacies has altered patient acquisition dynamics, bringing new entrants into the care continuum and challenging incumbent distribution models. As a result, manufacturers and service providers must re-evaluate product positioning, evidence generation strategies, and engagement models to meet both clinical and commercial objectives.

This introductory synthesis frames the remainder of the executive summary by outlining the systemic drivers reshaping the ED landscape. It highlights the interplay between clinical innovation, channel evolution, regulatory scrutiny, and patient centricity to set a strategic lens for stakeholders pursuing sustainable differentiation in a complex market environment.

How converging clinical, digital, and payer dynamics are reshaping therapeutic pathways and commercial strategies across the erectile dysfunction ecosystem

The landscape for erectile dysfunction treatment is experiencing transformative shifts driven by converging technological, regulatory, and consumer trends. First, therapeutic innovation has moved beyond incremental formulation changes to integrate novel delivery systems and device-based options, forcing a reappraisal of long-standing clinical pathways. These advances are prompting clinicians to weigh efficacy alongside durability, complication profiles, and patient lifestyle alignment, ultimately reshaping clinical guidelines and referral patterns.

Second, digital health and telemedicine have accelerated access to care and altered patient journeys, enabling discreet, rapid initiation of treatment while introducing new channels for ongoing monitoring and adherence support. Third, payer scrutiny and value-based contracting are increasingly influencing formulary positioning and device reimbursement, which drives manufacturers to invest in real-world evidence and health economics outcomes research. Fourth, supply chain resilience and manufacturing flexibility have gained prominence, encouraging strategic supplier diversification and localized sourcing where feasible.

Collectively, these shifts create both risk and opportunity: established players must adapt their commercialization playbooks, while agile entrants can leverage digital-first models and targeted clinical differentiation to capture underserved segments. The net result is an industry at an inflection point where integrated strategies across R&D, regulatory, and commercial functions are essential to capture long-term value.

Assessing supply chain exposure and strategic procurement responses to tariff-driven cost pressures that affect device components, drug ingredients, and distribution economics

Recent trade policy developments and the potential introduction of tariffs affecting medical imports have heightened scrutiny of supply chain exposure for manufacturers and suppliers of erectile dysfunction treatments. Tariffs can increase landed costs for devices and certain active pharmaceutical ingredients, prompting firms to reassess supplier contracts, inventory policies, and pricing strategies. In response, many organizations have accelerated procurement diversification, evaluated nearshoring options, and negotiated long-term supplier agreements to mitigate exposure to import cost volatility.

The cumulative operational impacts extend to manufacturing planning and inventory holding patterns. Companies reliant on specialized components for penile implants or device assemblies may encounter longer lead times and the need for qualified secondary suppliers, which in turn can influence time-to-patient and aftermarket support capabilities. For drug manufacturers and distributors, tariff-related cost pressures can affect wholesale pricing negotiations and channel margin structures, particularly in channels with high price sensitivity such as online and retail pharmacies.

Regulatory and compliance teams are also revisiting tariff-driven changes to customs classification and documentation requirements, while commercial teams explore reimbursement conversations informed by incremental cost structures. Importantly, firms are prioritizing scenario planning and cost pass-through analyses, while seeking to protect patient access by maintaining continuity of supply and preserving clinically appropriate treatment options despite potential trade headwinds.

A multi-dimensional segmentation framework tying treatment modality, product form, distribution route, care setting, administration route, and age cohorts to tactical commercial decisions

A nuanced segmentation framework is essential to understand patient need, commercialization pathways, and clinical adoption for erectile dysfunction treatments. Based on Treatment Type, the market is studied across oral agents, penile implants, penile injections, and vacuum erection devices; within oral agents the focus narrows to PDE5 inhibitors, which are further examined by molecule, including avanafil, sildenafil, tadalafil, and vardenafil, enabling differentiated clinical and marketing strategies for each therapeutic profile. Based on Product Type, the market is distinguished between devices and drugs, with devices categorized as penile implants, penile injections, and vacuum erection devices, and drugs discussed through the lens of PDE5 inhibitors and their individual active ingredients to clarify development priorities and lifecycle management approaches.

Based on Distribution Channel, the analysis considers clinic pharmacy, hospital pharmacy, online pharmacy, and retail pharmacy pathways to reveal channel-specific access barriers and revenue models. Based on End User, segmentation traces use across clinics, homecare settings, and hospitals to illuminate service delivery models and opportunities for patient education and remote monitoring. Based on Route of Administration, treatments are grouped into injectable, oral, and topical formats to align clinical preference and adherence considerations with commercialization tactics. Finally, based on Patient Age Group, the framework examines cohorts aged 40-49, 50-59, 60-69, and 70-plus to surface age-related prevalence patterns, comorbidity interactions, and tailored engagement approaches. Together, these segmentation lenses provide a comprehensive map for product development, evidence generation, and go-to-market prioritization that aligns with clinical behavior and patient expectations.

Regional differentiation in regulatory, reimbursement, and manufacturing realities that determines tailored market entry strategies and cross-border evidence leverage

Regional dynamics play a pivotal role in shaping regulatory pathways, reimbursement environments, and patient access for erectile dysfunction therapies. In the Americas, market maturity, robust private payer systems, and an established specialty distribution infrastructure support rapid adoption of novel oral agents and device technologies, while also presenting complex reimbursement negotiation dynamics. By contrast, Europe, Middle East & Africa presents a mosaic of national regulatory frameworks and heterogeneous payer landscapes that demand tailored pricing and market-access strategies, especially for high-cost devices or new therapeutic categories.

Asia-Pacific is characterized by fast-growing healthcare investment, diverse regulatory timelines, and a rising prevalence of lifestyle-related comorbidities that influence disease burden and treatment-seeking behavior. Regional manufacturing capabilities and supplier networks also vary significantly across these geographies, which affects sourcing decisions and time to market. Cross-region collaboration and strategic entry sequencing allow companies to leverage early evidence generation in one geography to support regulatory submissions and payer discussions in others, while local partnerships can accelerate market penetration and distribution reach.

Understanding these regional nuances is critical for designing differentiated launch strategies, prioritizing reimbursement dossiers, and aligning clinical evidence generation with the expectations of regulators, payers, and clinicians in each jurisdiction.

Competitive landscape synthesis showing how pharmaceutical incumbents, device innovators, and digital entrants are reshaping pathways to clinician trust and patient preference

Competitive dynamics in the erectile dysfunction space reflect a mix of established pharmaceutical innovators, specialized medical device manufacturers, and digitally native entrants that focus on direct-to-consumer care pathways. Leading pharmaceutical players maintain strong brand recognition for oral agents and continue to invest in lifecycle management, new formulations, and combination therapy research to preserve clinical relevance. Device manufacturers are increasingly differentiating through improvements in biocompatible materials, miniaturization, and surgical technique support, alongside aftermarket service models that emphasize long-term patient outcomes.

New entrants are leveraging telemedicine platforms and subscription-based distribution to acquire patients rapidly, which has altered traditional physician referral patterns and created pressure on channel margins. Partnerships between device firms and specialty clinics are becoming more common to deliver integrated treatment packages that combine procedure capability with ongoing patient management. Additionally, contract research organizations and real-world evidence partners play an expanding role in supporting health economics data generation necessary for formulary and reimbursement discussions.

In this competitive environment, organizations that align clinical differentiation with scalable distribution models and robust evidence-generation plans are best positioned to capture clinician trust and patient preference. Strategic collaborations, targeted investments in post-market surveillance, and clear value communication to payers will continue to separate leaders from followers.

Practical strategic initiatives for leaders to secure clinical credibility, operational resilience, and commercial scale through integrated evidence and channel diversification

Industry leaders seeking to accelerate growth and defend market position should adopt a set of pragmatic, high-impact actions. First, prioritize integrated evidence generation that combines randomized clinical data with robust real-world outcomes to support payer conversations and clinician adoption; investing early in health economics and quality-of-life measures will reduce reimbursement friction and strengthen product differentiation. Second, diversify supplier and manufacturing arrangements to insulate production from trade shocks, and develop contingency plans that preserve continuity of care and spare critical components.

Third, embrace channel diversification by optimizing presence across clinic pharmacy, hospital systems, online pharmacies, and retail outlets, while tailoring pricing and patient-support programs to channel-specific behaviors. Fourth, invest in digital engagement and telehealth integrations that enhance patient acquisition and adherence, enabling personalized care pathways that align with different age cohorts and administration routes. Fifth, pursue strategic alliances with specialty clinics, academic centers, and real-world evidence partners to accelerate adoption and create compelling case studies that illustrate long-term outcomes.

Finally, maintain regulatory agility by monitoring policy shifts and engaging proactively with authorities to clarify classification, reimbursement eligibility, and post-market obligations. Executing these recommendations in a coordinated manner will strengthen resilience, enhance commercial traction, and create defensible advantages in a dynamic competitive landscape.

Robust multi-method research approach integrating clinician interviews, regulatory review, and commercial intelligence to ensure evidence-based strategic guidance

The research methodology underpinning this analysis combines qualitative and quantitative approaches to deliver rigorous, actionable insights. Primary research consists of structured interviews and in-depth discussions with clinicians, payers, procurement specialists, and patient advocacy representatives to capture frontline perspectives on treatment choice drivers, reimbursement barriers, and care delivery constraints. These stakeholder engagements are complemented by advisory panels convened to validate hypotheses and surface emerging clinical practice patterns.

Secondary research includes systematic reviews of peer-reviewed clinical literature, regulatory guidelines, and product registries to ensure that device performance claims and therapeutic efficacy are interpreted within the appropriate scientific context. Commercial intelligence draws upon public filings, patent landscapes, clinical trial registries, and distributor channel mapping to assess competitive positioning and supply chain footprints. Data synthesis involves triangulation across sources, thematic analysis of qualitative insights, and scenario-based sensitivity testing to evaluate strategic options under differing regulatory and trade environments.

This multi-method approach ensures that conclusions reflect both macro-level trends and on-the-ground realities, providing a robust foundation for decision-making by clinical, commercial, and policy stakeholders.

Concise synthesis of strategic priorities emphasizing evidence integration, supply resilience, and digitally enabled patient pathways to secure long-term leadership

In summary, the erectile dysfunction landscape is at a strategic inflection point defined by innovations in pharmacology, device technologies, and digital care models, set against heightened payer scrutiny and evolving trade dynamics. Successful stakeholders will be those that translate clinical differentiation into clear value propositions for clinicians and payers while simultaneously building supply chain resilience and channel adaptability. The interplay between age-segmented patient needs, administration routes, and distribution channels underscores the need for tailored commercialization strategies that address adherence, convenience, and long-term outcomes.

Looking ahead, organizations that invest in integrated evidence generation, diversified procurement strategies, and digital-enabled patient engagement will be better positioned to navigate regulatory complexity and changing reimbursement norms. Cross-functional collaboration between R&D, regulatory, and commercial teams will accelerate the translation of innovation into sustained clinical and commercial impact. Ultimately, the path to leadership will require a mix of clinical credibility, operational excellence, and nimble market execution to meet evolving patient expectations and health-system requirements.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Erectile Dysfunction Market, by Product Type

  • 8.1. Device
    • 8.1.1. Penile Implants
    • 8.1.2. Penile Injections
    • 8.1.3. Vacuum Erection Devices
  • 8.2. Drug
    • 8.2.1. Avanafil
    • 8.2.2. Sildenafil
    • 8.2.3. Tadalafil

9. Erectile Dysfunction Market, by Treatment Type

  • 9.1. Oral Agents
  • 9.2. Penile Implants
  • 9.3. Penile Injections
  • 9.4. Vacuum Erection Devices

10. Erectile Dysfunction Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Erectile Dysfunction Market, by Patient Age Group

  • 11.1. 40-49
  • 11.2. 50-59
  • 11.3. 60-69
  • 11.4. 70+

12. Erectile Dysfunction Market, by Distribution Channel

  • 12.1. Clinic Pharmacy
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy

13. Erectile Dysfunction Market, by End User

  • 13.1. Clinics
  • 13.2. Homecare
  • 13.3. Hospitals

14. Erectile Dysfunction Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Erectile Dysfunction Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Erectile Dysfunction Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Erectile Dysfunction Market

18. China Erectile Dysfunction Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bayer AG
  • 19.6. Boston Scientific Corporation
  • 19.7. Cipla Limited
  • 19.8. Coloplast Group
  • 19.9. Dong A Socio Holdings Co. Ltd.
  • 19.10. Dr. Reddy's Laboratories Ltd.
  • 19.11. Eli Lilly and Company
  • 19.12. Endo International Plc
  • 19.13. Futura Medical Plc
  • 19.14. GlaxoSmithKline plc
  • 19.15. Lupin Limited
  • 19.16. Pfizer Inc.
  • 19.17. Sandoz International GmbH
  • 19.18. Sanofi S.A.
  • 19.19. Sun Pharmaceutical Industries Ltd.
  • 19.20. Teva Pharmaceutical Industries Ltd.
  • 19.21. Viatris Inc.
  • 19.22. Vivus, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ERECTILE DYSFUNCTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ERECTILE DYSFUNCTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 40-49, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 40-49, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 40-49, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 50-59, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 50-59, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 50-59, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 60-69, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 60-69, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 60-69, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 70+, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 70+, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 70+, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINIC PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINIC PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINIC PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)